405 related articles for article (PubMed ID: 23095709)
1. Modelling non-homogeneous stochastic reaction-diffusion systems: the case study of gemcitabine-treated non-small cell lung cancer growth.
Lecca P; Morpurgo D
BMC Bioinformatics; 2012; 13 Suppl 14(Suppl 14):S14. PubMed ID: 23095709
[TBL] [Abstract][Full Text] [Related]
2. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
4. Stochastic simulation of the spatio-temporal dynamics of reaction-diffusion systems: the case for the bicoid gradient.
Lecca P; Ihekwaba AE; Dematté L; Priami C
J Integr Bioinform; 2010 Nov; 7(1):150. PubMed ID: 21098882
[TBL] [Abstract][Full Text] [Related]
5. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.
Tham LS; Wang L; Soo RA; Lee SC; Lee HS; Yong WP; Goh BC; Holford NH
Clin Cancer Res; 2008 Jul; 14(13):4213-8. PubMed ID: 18594002
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
[TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling.
Gao L; Shao T; Zheng W; Ding J
Clin Transl Oncol; 2021 Jul; 23(7):1386-1393. PubMed ID: 33566305
[TBL] [Abstract][Full Text] [Related]
10. [Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report].
Zhao M; Yang H; He J
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):550-3. PubMed ID: 21645463
[No Abstract] [Full Text] [Related]
11. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.
Bie Z; Li Y; Li B; Wang D; Li L; Li X
Thorac Cancer; 2019 Sep; 10(9):1770-1778. PubMed ID: 31321919
[TBL] [Abstract][Full Text] [Related]
14. Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
Metro G; Cappuzzo F; Finocchiaro G; Toschi L; Crinò L
Ann Oncol; 2006 May; 17 Suppl 5():v37-46. PubMed ID: 16807461
[TBL] [Abstract][Full Text] [Related]
15. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.
Gatzemeier U; Shepherd FA; Le Chevalier T; Weynants P; Cottier B; Groen HJ; Rosso R; Mattson K; Cortes-Funes H; Tonato M; Burkes RL; Gottfried M; Voi M
Eur J Cancer; 1996 Feb; 32A(2):243-8. PubMed ID: 8664035
[TBL] [Abstract][Full Text] [Related]
16. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Li M; Li H; Cheng X; Wang X; Li L; Zhou T; Lu W
Pharm Res; 2013 May; 30(5):1400-8. PubMed ID: 23344908
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Hu X; Jiao S; Zhang S; Wang Z; Wang M; Huang C; Zheng R; Li K; Wang J; Wang Y; Ouyang X; Lv W; Cheng G; Hu C; Luo R; Sun Y
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):569-75. PubMed ID: 23075680
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin and gemcitabine in stage IV non small cell lung cancer: beyond cisplatin in palliative chemotherapy.
Tassinari D; Fochessati F; Arcangeli V; Panzini I; Ravaioli A; Sartori S
Lung Cancer; 2003 Jan; 39(1):107-8. PubMed ID: 12499103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
